Thyroid and cortisol endocrinopathies and survival in cancer patients treated with immune checkpoint inhibitors in UAE
Authors:
Open Access
- 6 February 2026
- journal article
- other
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (3)
Abstract
Background Immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs) of which endocrinopathies are among the most frequent. This study aimed to identify thyroid and cortisol-related endocrine-related adverse events (ERAEs) in a cohort of patients treated with ICIs and to examine survival differences between patients who developed endocrinopathies and those who did not. Methods We conducted a retrospective review of electronic medical records of adult patients who received ICIs between 2018 and 2023. Data were collected specifically on thyroid and cortisol-related ERAEs. Results Among 616 patients, 59 (9.6%) developed thyroid or cortisol-related ERAEs. The mean time to onset was 22.7 weeks. All thyroid-related events were post-thyroiditis hypothyroidism (n = 55), while all cortisol-related events were due to adrenocorticotropic hormone (ACTH) deficiency (n = 11). The majority of these events occurred in patients treated with anti–PD-1 agents, the most commonly used therapy in this cohort. Patients who developed ERAEs demonstrated improved overall survival during the follow-up period compared to those without endocrine toxicity. Conclusion In this cohort, systematic monitoring identified thyroid- and cortisol-related ERAEs in 9.6% of patients, consisting exclusively of post-thyroiditis hypothyroidism and ACTH deficiency. The occurrence of these endocrinopathies was associated with a favorable survival trend, underscoring the importance of early recognition and management of endocrine irAEs in patients receiving ICIs.Keywords
This publication has 21 references indexed in Scilit:
- Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanomaEndocrine Connections, 2022
- Immune-Related Adverse Events Associated With Outcomes in Patients With NSCLC Treated With Anti-PD-1 Inhibitors: A Systematic Review and Meta-AnalysisFrontiers in Oncology, 2021
- Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiencyScientific Reports, 2021
- Endocrine toxicities of immune checkpoint inhibitorsNature Reviews Endocrinology, 2021
- Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-AnalysisJournal of Immunotherapy, 2019
- Endocrine‐related adverse events associated with immune‐checkpoint inhibitors in patients with melanomaCancer Medicine, 2019
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to NormalizationCell, 2018
- Endocrine Toxicity of Cancer Immunotherapy Targeting Immune CheckpointsEndocrine Reviews, 2018
- Endocrinopathies with use of cancer immunotherapiesClinical Endocrinology, 2017
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced MelanomaJournal of Clinical Oncology, 2017